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INTRODUCTION
Breast cancer is one of the most common cancers in women 
and a major cancer death in women. The incidence of breast 
cancer in Korea continues to rise year by year, and its clinical 
characteristics are becoming closer to those observed in West-
ern countries [1].
Among the many genes that have been known to play im-
portant roles in breast carcinogenesis, 14-3-3 sigma (σ) has 
been directly implicated in the tumorigenesis of breast cancer 
[2]. 14-3-3 σ is a p53-dependent, negative regulator of the cell 
cycle and contributes to G2/M arrest [2] by inhibiting the for-
mation of the Cdc2-cyclin B1 complex [2,3]. It can also stabil-
ize p53 expression by blocking MDM2-mediated p53 ubiquiti-
nation [4]. 14-3-3 σ inactivation has been reported in various 
types of cancers, such as lung, prostate, and vulvar and oral 
squamous cell carcinoma [5-7]. This suggests that 14-3-3 σ 
acts as a tumor suppressor and its inactivation contributes to 
tumorigenesis by promoting cell cycle progression. Studies 
have shown that 14-3-3 σ is selectively inactivated by epigene-
tic silencing [5,6,8]. In fact, loss of 14-3-3 σ by hypermethyl-
ation of its promoter is reported to be one of the most consis-
tent molecular alterations discovered in breast cancer so far 
[9,10]. Recently, a few studies showed that 14-3-3 σ was also 
downregulated through ubiquitin-mediated proteolysis by es-
trogen-responsive finger protein (Efp), an estrogen-dependent 
E3 ubiquitin ligase [11]. Efp is a downstream target of estro-
gen receptor and mediates estrogen-induced cell growth, 
which implies possible involvement in the development of 
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Purpose: 14-3-3 sigma (σ) is considered to be an important tu-
mor suppressor and decreased expression of the same has 
been reported in many malignant tumors by hypermethylation at 
its promoter or ubiquitin-mediated proteolysis by estrogen- 
responsive ring finger protein (Efp). In this study, we investigated 
the significance of 14-3-3 σ expression in human breast cancer 
and its regulatory mechanism. Methods: Efp was silenced using 
small interfering RNA (siRNA) in the MCF-7 breast cancer cell line 
in order to examine its influence on the level of 14-3-3 σ protein. 
The methylation status of the 14-3-3 σ promoter was also evalu-
ated by methylation-specific polymerase chain reaction (PCR). 
The expression of Efp and 14-3-3 σ in 220 human breast carci-
noma tissues was assessed by immunohistochemistry. Other 
clinicopathological parameters were also evaluated. Results: Si-
lencing Efp in the MCF-7 breast cancer cell line resulted in in-
creased expression of 14-3-3 σ. The Efp-positive human breast 
cancers were more frequently 14-3-3 σ-negative (60.5% vs. 
39.5%). Hypermethylation of 14-3-3 σ was common (64.9%) 
and had an inverse association with 14-3-3 σ positivity (p= 
0.072). Positive 14-3-3 σ expression was significantly correlated 
with poor prognosis: disease-free survival (p=0.008) and dis-
ease-specific survival (p=0.009). Conclusion: Our data suggests 
that in human breast cancer, the regulation of 14-3-3 σ may in-
volve two mechanisms: ubiquitin-mediated proteolysis by Efp 
and downregulation by hypermethylation. However, the inactiva-
tion of 14-3-3 σ is probably achieved mainly by hypermethyl-
ation. Interestingly, 14-3-3 σ turned out to be a very significant 
poor prognostic indicator, which is in contrast to its previously 
known function as a tumor suppressor, suggesting a different 
role of 14-3-3 σ in breast cancer.
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human breast cancers. However, the exact mechanism of how 
14-3-3 σ is inactivated and its association with Efp in breast 
cancer has not been clearly elucidated. Studies on Efp and 14-
3-3 σ in human breast cancer are still very limited, and the bi-
ological significance remains unclear.
Therefore, in this study we investigated the regulatory mech-
anism of 14-3-3 σ in breast cancer. We also evaluated the ex-
pression pattern of 14-3-3 σ using clinicopathological features 
of human breast cancer to deepen our understanding of the 
role of 14-3-3 σ in breast cancer tumorigenesis and biology. In 
order to do this, we investigated whether silencing Efp could 
affect 14-3-3 σ expression in vitro. We also examined the ex-
pression of Efp and 14-3-3 σ in 220 cases of human breast can-
cer tissues using immunohistochemistry. To investigate the 
epigenetic silencing of 14-3-3 σ by methylation, we examined 
the methylation status of 14-3-3 σ promoter sites in breast can-
cer tissues by methylation-specific polymerase chain reaction 
(PCR). We subsequently correlated these findings with various 
clinicopathological variables, including the clinical outcome of 
the patients.
METHODS
Patients and tissue specimens
We analyzed the breast cancer registry program of the De-
partment of Surgery, Gangnam Severance Hospital, Yonsei 
University College of Medicine. Two hundred twenty cases of 
pure invasive ductal carcinoma (‘NOS ductal’ according to 
World Health Organization classification) were obtained from 
female patients who underwent surgery between 1996 and 
2001 in Gangnam Severance Hospital, Yonsei University Col-
lege of Medicine. Inclusion criteria were cases of pure invasive 
ductal carcinoma without evidence of remote metastasis. Ex-
clusion criteria were cases of specific histological types (medul-
lary, mucinous, papillary, tubular, lobular, etc.), inflammatory 
breast cancer, bilateral cases, and those in which tissue samples 
and clinical data, including the follow-up results, were unavail-
able. The median follow-up period was 72 months.
Paraffin-embedded tissue sections were selected from the 
pathological files of the Department of Pathology. As men-
tioned above, we obtained baseline data and follow-up results, 
including the clinicopathological characteristics. The histologic 
grade was determined using a Nottingham combined histo-
logic grade (Elston-Ellis modification of Scarff-Bloom-Rich-
ardson grading system) [12]: G1 (well-differentiated), G2 
(moderately-differentiated), and G3 (poorly-differentiated). 
Using a reverse Black method, the nuclear grade was deter-
mined to be grade 1 (well-differentiated), grade 2 (moderately-
differentiated), or grade 3 (poorly-differentiated). Disease-spe-
cific survival was defined as the time that elapsed from the date 
of surgery to the date of death due to breast cancer. The follow-
up period was defined as the time that elapsed between sur-
gery and death or the last available date of follow-up. In cases 
in which there was no outpatient record during the most re-
cent 1-year period, we determined the death of the corre-
sponding cases by making an inquiry, based on the Korean so-
cial security number, to the Korea National Statistical Office, 
the district office, and/or the police station.
This study was approved by Institutional Review Board of 
the Gangnam Severance Hospital, Yonsei University College 
of Medicine (approval number: 3-2014-0192).
Tissue microarray and immunohistochemical evaluation
A tissue microarray was constructed by ISU Abxis Co. 
(Seoul, Korea) from the paraffin-embedded blocks of 220 
breast cancer cases. Briefly, all cases were histologically re-
viewed and representative tumor areas were marked in the 
corresponding paraffin blocks. Two selected cylinders (2 mm 
in diameter) from two different tumor areas were included for 
each case. Normal control tissues were obtained from sur-
rounding normal breast tissue.
Immunohistochemical staining was done for estrogen re-
ceptor (ER), progesterone receptor (PR), c-erbB-2, p53, Efp, 
and 14-3-3 σ. The tissue microarray slides were deparaffinized 
by xylene two times and treated with 100%, 95%, and 80% 
ethanol, and then hydrated with distilled water. These slides 
were then treated with citric acid buffer (pH 6.0) and boiled in 
a microwave for 20 minutes for antigen retrieval. Intrinsic 
peroxidase activity was blocked using a solution containing 
3% hydrogen peroxide. Next, the slides were rinsed with tris-
buffer solution (TBS) and incubated with the primary anti-
bodies for ER, PR, c-erbB-2, p53, Efp, and 14-3-3 σ overnight 
at 4°C (Table 1). The slides were rinsed with TBS, and then 
the Vectastain universal elite ABC kit (Vector Laboratories, 
Burlingame, USA) was applied. The color development was 
Table 1. Primary antibodies for the immunohistochemical staining
Antibody Manufacturer Isotype Dilution
Efp BD Bioscience
   (Franklin Lakes, USA)
Mouse monoclonal 1:300
14-3-3 σ  IBL (Takasaki, Japan) Rabbit polyclonal 1:100
ER  Thermo Fisher Scientific 
   (Fremont, USA)
Mouse monoclonal 1:100
PR  Invitrogen (Carlsbad, USA) Mouse monoclonal 1:100
c-erbB-2  Thermo Fisher Scientific 
   (Fremont, USA)
Mouse monoclonal 1:100
p53  Invitrogen (Carlsbad, USA) Mouse monoclonal 1:100
Efp =estrogen-responsive ring finger protein; ER=estrogen receptor; PR=  
progesterone receptor.
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done with NovaRed (Vector Laboratories), and then the slides 
were counterstained with hematoxylin. The slides were finally 
mounted and observed under a microscope.
The immunohistochemical results were interpreted by two 
experienced pathologists. A positive reaction was determined 
by the ratio of cancer cells stained by the primary antibody to 
the total cancer cells in each slide (Figure 1). For ER and PR, a 
positive diagnosis was determined when intensely stained nu-
clei were seen in more than 10% of the total cancer cells [13]. 
For c-erbB-2, a positive reaction was determined when the 
cell membranes were evenly stained (score 2 or 3 by the four-
grade system) [14,15]. For p53 protein, a positive reaction was 
determined when intensely stained nuclei were seen in more 
than 5% of the total cancer cells. Efp and 14-3-3 σ expression 
was graded as 0 (if none of the tumor cells were positive), 1 (if 
up to 10% of the tumor cells were positive), 2 (if 10% to 50% 
of the tumor cells were positive), and 3 (if more than 50% of 
the tumor cells were positive) by the two pathologists inde-
pendently. The final diagnosis was determined as positive 
when the sum of the two independent scores was equal or 
more than five [16,17].
Methylation-specific PCR
We analyzed the methylation status of 14-3-3 σ in randomly 
selected samples from 111 cases. The methylation status of the 
samples was investigated by methylation-specific PCR, as de-
scribed previously [9,18]. Briefly, genomic DNA was extracted 
using Qiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, 
USA) from the formalin-fixed, paraffin-embedded tumor tis-
sue after manual microdissection under a microscope to ob-
tain a sample that consisted of more than 70% tumor cells. One 
microgram of genomic DNA was then treated with sodium bi-
sulfite using an EZ DNA Methylation-Gold Kit (Zymo Re-
search, Orange, USA) and was analyzed by methylation-specif-
ic PCR (MSP) using a primer set that covered CG dinucleotide 
numbers 3, 4, 8, and 9. Primers specific for methylated DNA 
(59-TGGTAGTTTTTATGAAAGGCGTC-39 [sense] and 
59-CCTCTAACCGCCCACCACG-39 [antisense]), and prim-
ers specific for unmethylated DNA (59-ATGGTAGTTTT-
TATGAAAGGTGTT-39 [sense] and 59-CCCTCTAAC-
CACCCACCACA-39 [antisense]) yielded a 105 to 107-bp 
PCR product. The PCR conditions were as follows: 1 cycle of 
95°C for 5 minutes; 31 cycles of 95°C for 45 seconds, 56°C for 
30 seconds for the unmethylated primer, 60°C for 30 seconds 
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Figure 1. The increased expression of 14-3-3 σ by knocks down of estrogen-responsive ring finger protein (Efp) using small interfering RNA (siRNA). 
siEfp was transfected in human MCF-7 breast cancer cells. After transfection, total RNA and whole cell lysates were prepared and subjected to re-
verse transcription polymerase chain reaction (A) and Western blot (C). Relative levels of mRNA and protein expression were determined by densito-
metric scanning of the bands (B, D). The siEfp transfection resulted in increased levels of 14-3-3 σ mRNA and protein.
*Corresponds to p<0.05.
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for the methylated primer, and 72°C for 30 seconds; and 1 cycle 
of 72°C for 4 minutes.
The MCF-7 cell line, previously reported to be unmethyl-
ated at the 14-3-3 σ promoter [9], was used as the unmethyl-
ated control. Commercially available methylated DNA (Uni-
versal Methylated Human DNA Standard; Zymo Research) 
was used as the methylated control. Methylated bands on MSP 
which were more dense than the corresponding unmethylated 
bands or the ones as dense as the universally methylated DNA 
control were determined as hypermethylated.
Small interfering RNA silencing of Efp
For the transfection procedure, MCF-7 cells were grown to 
60% confluence, and Efp small interfering RNAs (siRNAs) 
(5'-GGTGGAGCAGCTACAACAATT-3') were transfected us-
ing the RNAiMax reagent (Invitrogen, Carlsbad, USA) accord-
ing to the manufacturer’s instructions. Briefly, the RNAiMax 
reagent was incubated with serum-free medium for 10 minutes. 
Subsequently, a mixture of the siRNA was added. After incuba-
tion for 15 minutes at room temperature, the mixture was di-
luted with medium and added to each well. The final concen-
tration of siRNAs in each well was 100 nM. After culturing for 
40 hours, cells were washed, resuspended in new culture media 
for reverse transcription (RT)-PCR and Western blot. Total 
RNA and whole cell lysates was prepared and subjected to RT-
RCR and Western blot. Relative levels of mRNA and protein 
expression were determined by densitometry of the bands.
RT-PCR analysis and Western blot
Confluent MCF-7 cell monolayers were washed with PBS. 
Total RNA (12 μg) was isolated using TRIzol reagent. One mil-
liliter of TRIzol reagent (Invitrogen) per well was added to cells 
in 6-well plates, and total RNA was extracted using the manu-
facturer’s protocol (Invitrogen). RT was performed using oligo 
(dT) primers and superscript reagent (Invitrogen). Five micro-
grams of RNA were used for first strand cDNA synthesis using 
oligo (dT) in a final volume of 20 μL. Seven microliters of the 
cDNA mixture was used to amplify mRNA for Efp, 14-3-3 σ, 
and 18s ribosomal RNA (18s rRNA) as a loading control by 
PCR. Efp, 14-3-3 σ, and 18s rRNA were amplified using the fol-
lowing primer sets: Efp (forward 5'-AACATCTCTCAAGGC-
CAAGGT-3' and reverse 5'-AGATGCCTACCCCACAG AA-
GT-3'), 14-3-3 σ (forward 5'-GTGTGTCCCCAGAGCATGG-3' 
and reverse 5'-ACCTTCTCCCGGTACTCA CG-3'), and 18s 
rRNA (forward 5'-CGGCTACCACATCCAAGGAA-3' and 
reverse 5'-GCTGGAATTACCGCGGCT-3'). The RT product 
(7 μL) was amplified in a 20-μL volume containing 10 pmol of 
primers and 2.5 units of Taq DNA polymerase. Reaction con-
ditions were as follows: 95°C for 1 minute, 60°C for 1 minute, 
72°C for 1 minute for 33 cycles, and then 72°C for 7 minutes. 
The PCR products were resolved on a 1.2% agarose gel and 
identified by ethidium bromide staining. Normalization of Efp 
and 14-3-3 σ expression was achieved by comparing the ex-
pression of 18s rRNA for the corresponding sample.
For Western blot analysis, proteins were isolated from MCF-
7 and siEfp-treated MCF-7 cells and lysed in solubilizing buffer 
(1× PBS, 1% nonidet P-40, 0.5% sodium deoxycholate, 0.1% 
SDS, protease inhibitors, PMSF, aprotinin, and sodium or-
thovandate). Equal amounts of protein extracts were separated 
by 10% SDS-PAGE and transferred to PVDF membrane (Mil-
lipore, Billerica, USA). The membrane was blocked with 5% 
nonfat milk in TBS containing 0.05% Tween, and then incu-
bated with antibody mouse anti-Efp (1:5,000; BD Bioscience, 
Franklin Lakes, USA), rabbit anti-14-3-3 σ (1:1,000; IBL Co., 
Ltd., Takasaki, Japan), and mouse antiactin (1:5,000; Santa 
Cruz Biotechnology, Santa Cruz, USA). The membrane was 
then incubated with the secondary antibody and thoroughly 
washed. Immunoreactive bands were visualized with a Super-
Signal (Thermo-Fisher Scientific, Waltham, USA).
Statistical analyses
All statistical analyses were done using SPSS version 13.0 for 
Windows (SPSS Inc., Chicago, USA). To evaluate correlations 
between Efp, and 14-3-3 σ expression and clinicopathologic 
parameters, data were cross-tabulation (chi-square test/2× 2 
table; Pearson or Fisher exact test) was done. Univariate analy-
sis with patient survival was evaluated using life tables con-
structed from survival data with Kaplan-Meier plots. Compar-
isons of the different groups were done with the log-rank test. 
The end point in the present study was disease-specific surviv-
al ranging from the date of surgery until the date of breast can-
cer-related death or, if no information was documented, until 
the date of last follow up information (= censored). Multivari-
ate survival analysis was carried out on samples where all clini-
cal parameters were available using the Cox proportional haz-
ard model to evaluate the independent power of each variable. 
Statistical significance was set at p-value < 0.05 (95% level of 
confidence).
RESULTS
Demographic data of the subjects
Basic clinical and demographic data are summarized in Ta-
ble 2. Mean patient age was 47.1± 9.9 years old. 66.3% (146/ 
220) are positive to at least one of the ER, PR, and HER2 (re-
ceptor-positive group). ER-positive cases, 19.5% (43/220) were 
HER2-positive cases, and all receptor groups were negative in 
26.4% (58/220), i.e., the triple-negative group. The triple-nega-
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tive group frequently showed high nuclear grade, high histo-
logic grade, and p53 positive cells.
Efp silencing upregulates 14-3-3 σ expression in vitro
Efp silencing was performed by transfection of siEfp in the 
human breast cancer cell line, MCF-7. Transfection of siRNA 
resulted in the downregulation of Efp mRNA levels by RT-PCR 
and increased the expression of 14-3-3 σ protein levels by 
Western blot (Figure 1). All three independent experiments 
gave similar results. This clearly shows that Efp is associated 
with decreased expression of 14-3-3 σ, and silencing of Efp can 
increase the expression of 14-3-3 σ.
Expression of Efp and 14-3-3 σ in subtypes of breast cancer
Both Efp and 14-3-3 σ showed cytoplasmic staining pat-
terns. 14-3-3 σ was strongly expressed in the myoepithelial 
cells. In the normal breast epithelial cells, Efp was only weakly 
positive. About two-thirds of the total tumors (146/217 cases, 
67.3%) were negative for both Efp and 14-3-3 σ. About one-
third of the total cases (71/217 cases, 32.7%) were positive for 
at least one of the two genes. Fifty-four of 217 cases (24.9%) 
were positive for only one of the two genes, while only 17 of 
217 cases (7.8%) showed positive staining for both. For the 
cases when at least one gene was positive, the majority (54/71 
cases, 76%) demonstrated a mutually exclusive pattern of pos-
itivity, i.e., positive to only one of the two proteins (Table 3, 
Figure 2). Only 17 cases (23.9%) of the positive 71 cases were 
positive for both Efp and 14-3-3 σ. The Efp-positive cases 
were more frequently negative (26/43 cases, 60.5%) for 14-3-3 
σ than positive (17/43 cases, 39.5%).
The majority (36/43 cases, 85.7%) of the Efp-positive tumors 
were receptor-positive (p= 0.019). Triple-negative tumors were 
more frequently positive for 14-3-3 σ (19/58 cases) than recep-
tor-positive tumors (26/145 cases) (p= 0.006) (Table 4).
Correlation between Efp, 14-3-3 σ expression, and 
clinicopathological variables
Correlation between Efp, 14-3-3 σ expression status, and 
other clinicopathological parameters of patients are summa-
rized in Table 5. Notably, Efp was negatively correlated with 
axillary lymph node metastasis (p= 0.021) or positive p53 ex-
Table 2. Baseline clinicopathologic characteristics of breast cancer pa-
tients examined
Characteristic
Subgroup*
p-value§Receptor (+)
†
(n=129) 
No. (%)
Triple (-)‡
(n=58)
No. (%)
HER2 only (+)
(n=17)
No. (%)
Age (yr)II 46.9±10.1 47.0±10.1 49.1±8.1 0.939¶
Follow-up (mo)** 72 (1–144) 73 (5–135) 83 (7–135) 0.648¶
Tumor size (cm)
   ≤2 54 (74.0) 18 (24.7) 1 (1.4) 0.010
   >2 75 (57.3) 40 (30.5) 16 (12.2)
Axillary node
   Negative 59 (58.4) 33 (32.7) 9 (8.9) 0.353
   Positive 70 (68.0) 25 (24.3) 8 (7.8)
Stage
   I 33 (71.7) 13 (28.3) 0 0.178
   II 70 (61.4) 33 (28.9) 11 (9.6)
   III 26 (59.1) 12 (27.3) 6 (13.6)
Histologic grade
   I 36 (87.8) 3 (7.3) 2 (4.9) 0.001
   II & III 93 (57.4) 54 (33.3) 15 (9.3)
Nuclear grade
   1 & 2 84 (79.2) 17 (16.0) 5 (4.7) <0.001
   3 44 (45.8) 40 (41.7) 12 (12.5)
ER
   Negative 43 (36.4) 58 (49.2) 17 (14.4) -
   Positive 86 (100.0) 0 0 
PR
   Negative 18 (19.4) 58 (62.4) 17 (18.3) -
   Positive 111 (100.0) 0 0 
HER2
   Negative 103 (64.0) 58 (36.0) 0 -
   Positive 26 (60.5) 0 17 (39.5)
p53
   Negative 98 (75.4) 26 (20.0) 6 (4.6) <0.001
   Positive 27 (39.1) 31 (44.9) 11 (15.9)
ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal 
growth factor receptor 2.
*Excluding unknown cases; †Receptor-positive group: positive to at least one 
of the ER, PR, and HER2; ‡Triple-negative group: negative to all of the ER, PR, 
and HER2; §p-value from chi-square test (2×2 Pearson or Fisher exact test; 
except TNM stage); IIMean±SD; ¶p-value of age and follow-up duration: from 
independent sample t-test; **Median (range).
Table 3. Correlation between Efp and 14-3-3 σ expression
No.
Efp
p-value*Negative
No. (%)
Positive
No. (%)
Total 14-3-3 σ <0.001
   Negative 172 146 (84.9) 26 (15.1)
   Positive 45 28 (62.2) 17 (37.8)
   Total† 217 174 43
Hormonal receptor-positive <0.001
   14-3-3 σ
   Negative 108 87 (80.6) 21 (19.4)
   Positive 20 8 (40.0) 12 (60.0)
   Total† 128 95 33
Triple-negative 14-3-3 σ 0.067
   Negative 38 36 (94.7) 2 (5.3)
   Positive 19 15 (78.9) 4 (21.2)
   Total† 57 51 6
Efp =estrogen-responsive ring finger protein.
*p-value from chi-square test (2×2 Pearson); †Total number of the group (ex-
cluding unknown cases).
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pression (p= 0.009). There was an increase in the proportion 
of Efp-negative cases as the histologic grade and nuclear grade 
increased, but it was not statistically significant. No other clin-
icopathological variables, such as tumor size, stage, histologic 
grade, nuclear grade, ER, or c-erbB-2 appeared to be signifi-
cantly related to Efp expression.
Positive 14-3-3 σ expression was significantly correlated 
with high histologic grade, high nuclear grade, and positive 
p53 (p= 0.012, p= 0.033, and p= 0.001, respectively). There 
was a statistically significant inverse correlation between 14-3-
3 σ expression and both ER-positivity (p= 0.020) and PR-pos-
itivity (p= 0.032), which is in accordance with our previous 
finding that the triple-negative group was more frequently 14-
3-3 σ-positive than the receptor-positive group.
MSP for the 14-3-3 σ promoter
Methylation status of the 14-3-3 σ promoter was evaluated 
with MSP, as shown in Figure 3. Of the 111 cases examined, 72 
cases (64.9%) were hypermethylated by MSP (Table 6). The 
A B
C D
Figure 2. Expression of estrogen-responsive ring finger protein (Efp) and 14-3-3 σ in breast cancer. An estrogen receptor-positive breast cancer was 
positive to Efp (A) and negative to 14-3-3 σ (B) while a triple-negative breast cancer was negative to Efp (C) and positive to 14-3-3 σ (D) (NovaRed 
with Hematoxylin counterstain, ×400).
Table 4. Expression of Efp and 14-3-3 σ according to the subtype of 
breast cancer by receptor expression
 
Receptor-positive 
(n=128)*
No. (%)
Triple-negative 
(n=57)*
No. (%)
p-value†
Efp 0.019
   Negative 95 (74.2) 51 (89.5)
   Positive 33 (25.8) 6 (10.5)
14-3-3 σ 0.006
   Negative 108 (84.4) 38 (66.7)
   Positive 20 (15.6) 19 (33.3)
Efp =estrogen-responsive ring finger protein.
*Excluding unknown cases; †p-value from chi-square test.
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hormone receptor-positive group was more frequently hyper-
methylated (45/71 cases, 63.4%) than the triple-negative group 
(17/28 cases, 60.7%), but the difference was not statistically sig-
nificant (Table 6). The 14-3-3 σ positive results by immunohis-
tochemistry were negatively associated with the hypermethyl-
ation of the 14-3-3 σ promoter, but only showed marginal sig-
nificance (p= 0.072) (Table 6).
Correlation between Efp, 14-3-3 σ expression, and clinical 
outcome
Univariate analysis of various clinicopathological factors 
that may be correlated with the expression of Efp and 14-3-3 
Table 5. The correlations between the Efp, 14-3-3 σ, and other clinicopathological parameters
Clinicopathologic
   parameters
No.*
Efp 14-3-3 σ
Negative
No. (%)
Positive
No. (%)
p-value†
Negative
No. (%)
Positive
No. (%)
p-value†
Tumor size (cm) 0.236 0.630
   ≤2 79 60 (75.9) 19 (24.1) 64 (81.0) 15 (19.0)
   >2 138 114 (82.6) 24 (17.4) 108 (78.3) 30 (21.7)
Axillary node 0.021 0.346
   Negative 107 79 (73.8) 28 (26.2) 82 (76.6) 25 (23.4)
   Positive 110 95 (86.4) 15 (13.6) 90 (81.8) 20 (18.2)
Stage 0.196 0.692
   I 48 36 (75.0) 12 (25.0) 39 (81.3) 9 (18.8)
   II 123 97 (78.9) 26 (21.1) 95 (77.2) 28 (22.8)
   III 46 41 (89.1) 5 (10.9) 38 (82.6) 8 (17.4)
Histologic grade 0.061 0.012
   I 43 30 (69.8) 13 (30.2) 40 (93.0) 3 (7.0)
   II & III 172 142 (82.6) 30 (17.4) 130 (75.6) 42 (24.4)
Nuclear grade 0.052 0.033
   1 & 2 111 83 (74.8) 28 (25.2) 94 (84.7) 17 (15.3)
   3 103 88 (85.4) 15 (14.6) 75 (72.8) 28 (27.2)
ER 0.086 0.020
   Negative 126 106 (84.1) 20 (15.9) 93 (73.8) 33 (26.2)
   Positive 91 68 (74.7) 23 (25.3) 79 (86.8) 12 (13.2)
PR 0.022 0.032
   Negative 99 86 (86.9) 13 (13.1) 72 (72.7) 27 (27.3)
   Positive 117 87 (74.4) 30 (25.6) 99 (84.6) 18 (15.4)
HER2 0.965 0.544
   Negative 160 127 (79.4) 33 (20.6) 126 (78.8) 34 (21.3)
   Positive 43 34 (79.1) 9 (20.9) 32 (74.4) 11 (25.6)
p53 0.009 0.001
   Negative 130 97 (74.6) 33 (25.4) 110 (84.6) 20 (15.4)
   Positive 70 63 (90.0) 7 (10.0) 45 (64.3) 25 (35.7)
Efp =estrogen-responsive ring finger protein; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2.
*Total number of the group (excluding unknown cases); †p-value from chi-square test (2×2 Pearson; except TNM stage).
Figure 3. Methylation-specific polymerase chain reaction (MSP) in breast cancer. Methylated and unmethylated bands on MSP. Methylated bands 
which are brighter than the corresponding unmethylated band or the ones as dense as the universally methylated DNA control were determined as 
hyper-methylated.
8, 18, 74, 78, and 92=case numbers; MCF=MCF-7 cell line; PC=universally methylated DNA; U=unmethylated band; M=methylated band.
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σ showed that 14-3-3 σ expression was significantly associated 
with an increased risk of recurrence and disease-related death 
(p= 0.011 and p= 0.022), while Efp was not. Other tradition-
ally well-known prognostic factors, such as tumor size, axil-
lary lymph node status, TNM stage, and histologic grade, 
were also significant prognostic variables for survival (data 
not shown).
Multivariate analysis revealed that the axillary lymph node 
status (p= 0.028) and 14-3-3 σ expression (p= 0.008) were the 
only two independent prognostic factors for recurrence with 
relative risks over 1.0, whereas tumor size, TNM stage, and 
histologic grade were not significant (Table 7). Only TNM 
stage (p= 0.015) and 14-3-3 σ expression (p= 0.009) were in-
dependent prognostic factors in cancer-related deaths, but 
other factors including Efp were not significant prognostic in-
dicators (Table 7).
In both the univariate and multivariate analysis, 14-3-3 σ 
appeared to be the single most powerful prognostic indicator. 
Survival curves based on 14-3-3 σ expression also demon-
strated a significant correlation between positive 14-3-3 σ ex-
pression and adverse clinical outcome of the patients (Figure 
4A and 4B). This correlation appeared to be more pronounced 
in the triple-negative group (Figure 4E and 4F) than in the re-
ceptor-positive group (Figure 4C and 4D). In the receptor-
positive group, the difference between the 14-3-3 σ positive 
group and negative group was not statistically significant.
DISCUSSION
The role of the 14-3-3 σ as a tumor suppressor has been 
shown by its known function as a negative cell cycle regulator, 
a G2/M checkpoint by inhibiting the formation of the Cdc2-
Table 6. 14-3-3 σ expression and its methylation status in breast cancer
Methylation status No.*
14-3-3 σ
Negative
No. (%)
Positive
No. (%)
p-value†
Overall case
   Methylation 0.072
      Unmethylated 38 26 (68.4) 12 (31.6)
      Methylated 72 60 (83.3) 12 (16.7)
Receptor-positive group
   Methylation 0.182
      Unmethylated 25 19 (76.0) 6 (24.0)
      Methylated 43 38 (88.4) 5 (11.6)
Triple-negative group
   Methylation 0.094
      Unmethylated 11 5 (45.5) 6 (54.5)
      Methylated 17 13 (76.5) 4 (23.5)
*Total number of the group (excluding unknown cases); †p-value from chi-
square test (2×2 Pearson).
Table 7. Multivariate analysis of recurrence and cancer-related death
Coefficient SE RR (95% CI) p-value*
For recurrence
   Tumor size (cm)
      ≤2 - - 1.0
      >2 0.854 0.493 2.350 (0.894–6.172) 0.083
   Axillary node
      Negative - - 1.0
      Positive 1.071 0.487 2.917 (1.123–7.576) 0.028
   TNM stage 0.077
      I - - 1.0
      II -0.066 0.952 0.936 (0.145–6.051) 0.945
      III 0.772 1.012 2.165 (0.298–15.743) 0.445
   Histologic grade
      I - - 1.0
      II & III 0.929 0.746 2.531 (0.586–10.926) 0.213
   14-3-3 σ 
      Negative - - 1.0
      Positive 0.937 0.351 2.551 (1.283–5.075) 0.008
For cancer-related 
   death
   Tumor size (cm)
      ≤2 - - 1.0
      >2 -0.912 0.634 2.489 (0.719–8.620) 0.150
   Axillary node
      Negative - - 1.0
      Positive 0.449 0.586 1.567 (0.497–4.948) 0.443
   TNM stage 0.015
      I - - 1.0
      II -0.279 1.046 0.756 (0.097–5.877) 0.789
      III 1.144 1.133 3.139 (0.341–28.890) 0.313
   Histologic grade
      I - - 1.0
      II & III 1.052 1.042 2.864 (0.372–22.071) 0.312
   14-3-3 σ
      Negative - - 1.0
      Positive 1.116 0.428 3.502 (1.319–7.063) 0.009
Data were considered significant in the univariate analyses and were exam-
ined in the multivariate analyses. Relative risk (RR) less than 1.00 represent a 
decreased risk of death, whereas RR greater than 1.00 represent an in-
creased risk of death.
SE=standard error; CI=confidence interval.
*p-values determined by a Cox proportional hazard model.
cyclin B1 complex [2,3], or by stabilizing p53 through block-
ing MDM2-mediated p53 ubiquitination [4]. This has been 
supported by several observations of decreased expression of 
14-3-3 σ in various malignant tumors, such as cancer of the 
stomach, prostate, lung, and oral cavity [5-8]. In breast cancer, 
14-3-3 σ expression has also been shown to be downregulated 
[9,10,19]. The mechanism by which 14-3-3 σ is inactivated 
has not been completely elucidated yet, but epigenetic silenc-
ing by hypermethylation of the 14-3-3 σ gene is one of the 
commonly proposed mechanisms [5,8-10].
A previous study demonstrated that 14-3-3 σ expression was 
gradually decreased as a lesion progressed from benign to ma-
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lignant with the loss of 14-3-3 σ expression in 8%, 35%, and 
77% of usual ductal hyperplasia, ductal carcinoma in situ 
(DCIS), and invasive ductal carcinoma (IDC) lesions, respec-
tively, which indicates the role of 14-3-3 σ as a tumor suppres-
sor in breast carcinogenesis [20]. Another recent study showed 
that the hypermethylation of 14-3-3 σ occurred at rates of zero 
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Figure 4. Disease-free survival and disease-specific survival curves according to 14-3-3 σ expression in each subgroup.  (A, C, E) Disease-free survival; 
(B, D, F) Disease-specific survival. (A, B) Total cases: 14-3-3 σ expression was significantly associated with an increased risk of recurrence and disease-
related death. (C, D) Receptor-positive group: 14-3-3 σ expression was associated with an increased risk of recurrence and disease-related death, but 
statistically insignificant. (E, F) Triple-negative group: 14-3-3 σ expression was not associated with an increased risk of recurrence. But 14-3-3 σ ex-
pression was significantly associated with an increased risk of disease-related death. Dashed line, 14-3-3 σ negative; linear line, 14-3-3 σ positive.
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in hyperplasia without atypia, 38% in atypical hyperplasia, 
83% in DCIS, and 96% in IDC [10]. These studies showing a 
gradual decrease in 14-3-3 σ expression and a corresponding 
increase of hypermethylation with progression of the breast le-
sions, and the fact that hypermethylation of the 14-3-3 σ gene 
was also found in some benign, and sometimes even appar-
ently normal epithelia adjacent to cancer, suggest and support 
the idea that 14-3-3 σ inactivation by hypermethylation may 
be an early event in breast carcinogenesis [10,19].
On the other hand, it has also been reported that 14-3-3 σ is 
a primary target for proteolysis by Efp, and expression of the 
14-3-3 σ protein is regulated by ubiquitin-mediated proteo-
lysis by Efp in vitro [11,21]. Efp is a RING finger-dependent 
protein and functions as a ubiquitin-ligase (E3) that can ubiq-
uitinate 14-3-3 σ [11,21]. Our experimental data suggested 
that the Efp may promote unlimited proliferation of breast 
cancer cells by accelerated destruction of 14-3-3 σ, a postulat-
ed cell cycle inhibitor. This is supported by another recent 
study in human breast cancer tissue which showed that im-
munoreactivity of 14-3-3 σ was inversely associated with Efp 
immunoreactivity [22].
In our study, we demonstrated that silencing Efp can result 
in increased expression of 14-3-3 σ in the MCF-7 breast cancer 
cell line. In human breast tissue, we found that the Efp-positive 
cases were more frequently 14-3-3 σ negative. This in vitro and 
in vivo counter-correlation between Efp and 14-3-3 σ possibly 
supports the Efp-mediated ubiquitination of 14-3-3 σ in breast 
cancer. However, the MCF-7 cell line we used in Efp-silencing 
is known to be luminal ER-positive in phenotype. We did not 
test basal-like cell lines. The ER-negative, basal-like cell lines 
might have low baseline Efp levels, which might compromise 
the silencing effect. The difference in the 14-3-3 σ responsive-
ness to Efp in different cell lines requires further investigation.
Efp positivity was not common in our cohort with since only 
about one-fourth of the total cases were positive for Efp where-
as 14-3-3 σ was negative in about two-thirds of the total cases. 
In contrast, hypermethylation of 14-3-3 σ was common, occur-
ring in more than 60% of the breast cancer samples. This may 
suggest that even if Efp can ubiquitinate and accelerate the deg-
radation of 14-3-3 σ in vitro and even in vivo, it may not be a 
dominant mechanism in the inactivation of human breast can-
cer. Instead, hypermethylation may play a major role in the in-
activation of 14-3-3 σ in human breast cancer.
The Efp is also a downstream target of estrogen receptor α 
(ERα) [23-25]. In a previous study, Efp immunoreactivity was 
significantly associated with ERα status in breast carcinoma 
tissues [24]. The Efp gene has an estrogen-responsive element 
at the 3’-untranslated region [23]. Therefore, it has been sug-
gested that Efp is mainly produced in carcinoma cells through 
ERα as a result of estrogenic action in breast carcinoma. How-
ever, in our study there was no significant correlation between 
Efp and ER. In our study, the frequency of Efp positive cancers 
was low, only 36 of 145 cases (24.8%) in the receptor-positive 
group. It was even lower in the triple-negative group (positive 
in 6/57 cases, 10.5%). Suzuki et al. [22] found higher Efp im-
munoreactivity in ERα-negative breast carcinomas (52.4%). 
This difference in the frequency of Efp positivity in ER-nega-
tive breast cancers may be partially due to the difference in the 
criteria by which immunohistochemical positivity was deter-
mined. In our study, we used strict criteria, considering only 
diffuse strong expression (grade 3) as positive. Another possi-
ble explanation for the lack of correlation between Efp and 
ERα status is the escape of breast cancer cells from estrogenic 
control in tumorigenesis, as suggested in another recent study 
[25]. Ikeda et al. [26] suggested another possibility by analyz-
ing the 5’-flanking region of the human Efp gene, and report-
ing the regulation of the Efp promoter by multiple elements 
and/or interacting factors. Therefore, factors other than ERα 
may be also be involved in the expression of Efp in some breast 
carcinomas. Suzuki et al. [22] reported that Efp immunoreac-
tivity was significantly associated with an increased risk of re-
currence or worse prognosis for both recurrence and overall 
survival in breast carcinomas, and that the effect is similar to 
that of the lymph node status, a well-established prognostic 
factor. However, in our study Efp expression was inversely cor-
related with axillary lymph node status (p= 0.021) although it 
was not significantly associated with patient survival.
Interestingly, in contrast to previous reports showing de-
creased expression or inactivation of 14-3-3 σ in various ma-
lignant tumors supporting its function as a tumor suppressor, 
the current results clearly show that 14-3-3 σ expression was 
not lost, but strongly expressed in at least a small subset of 
breast cancer cases. Although 14-3-3 σ expression in breast 
cancer was not compared to that in normal breast epithelia or 
benign proliferative lesions, another result of our study re-
vealed the significant correlation of 14-3-3 σ positivity with 
high grade breast cancers and poor prognosis also clearly 
shows that 14-3-3 σ may play a more complicated role than 
just a tumor suppressor in breast cancer. In our study, the ex-
pression of 14-3-3 σ was inversely correlated with ERα, PR, 
and even Efp, which partially explains the more frequent posi-
tivity in triple-negative tumors than in receptor-positive tu-
mors. In addition, 14-3-3 σ is correlated with high histologic 
grade, high nuclear grade, and positive p53 expression, all of 
which are characteristics of triple-negative breast cancers. The 
significance of 14-3-3 σ as a poor prognostic indicator was 
also more pronounced in triple-negative tumors than in re-
ceptor-positive ones. This association of 14-3-3 σ with poor 
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prognosis was in contrast to the previously known function of 
14-3-3 σ as a tumor suppressor. However, the role of 14-3-3 σ 
as a poor prognostic factor has also been reported by a few re-
cent studies in other types of cancer. Perathoner et al. [27] re-
ported that 14-3-3 σ was significantly correlated with tumor 
differentiation and stage in colorectal carcinoma, and clearly 
demonstrated that 14-3-3 σ was an independent poor prog-
nostic marker. Nakayama et al. [28] examined the expression 
of 14-3-3 σ, ERα, and Efp in endometrial carcinomas and 
showed that high 14-3-3 σ expression was significantly corre-
lated with myometrial invasion and lymph node metastasis. 
The expression of 14-3-3 σ in normal and hyperplastic endo-
metrium was also evaluated, and demonstrated that interest-
ingly 14-3-3 σ expression gradually decreased from normal to 
hyperplastic to malignant tumors, which is a similar result to 
the previous studies [5-8,20]. These conflicting findings on the 
role of 14-3-3 σ in various types of cancer suggest that 14-3-3 
σ is not just a tumor suppressor. Instead, it may have a more 
complex and complicated role in the process of carcinogene-
sis. It might also be possible that it plays different roles in early 
and late carcinogenesis. In early carcinogenesis, when malig-
nant transformation occurs from the normal epithelium, 14-
3-3 σ may function as a tumor suppressor, but once a malig-
nant tumor is established, it may have a role in promoting tu-
mor growth and propagation. Another hypothesis is that the 
deregulation or dysfunction of the ubiquitin-proteosome 
pathway may result in accumulation of 14-3-3 σ despite of the 
high level of Efp. Deregulation or dysfunction of the ubiqui-
tin-proteosome pathway has been reported in various diseas-
es, mainly neurodegenerative or metabolic diseases [29]. 
There is also evidence that the ubiquitin-proteosome system 
plays a role in tumor development, such as in colon cancer or 
hepatocellular carcinoma [30], in which the system is not ex-
actly dysregulated, but activated degrading the tumor suppres-
sor molecules. The exact role of 14-3-3 σ in breast and other 
cancers needs to be further elucidated. However, the signifi-
cant correlation of 14-3-3 σ and poor prognosis suggests its 
potential usefulness as a therapeutic target in breast cancer.
Our data demonstrated that 14-3-3 σ was negatively corre-
lated with Efp in vitro and less frequently in vivo. 14-3-3 σ was 
negatively correlated with hypermethylation in human breast 
cancer tissue, which was more common. This suggests that in 
human breast cancers the regulation of 14-3-3 σ may involve 
both mechanisms, i.e., ubiquitin-mediated proteolysis by Efp 
and downregulation by hypermethylation. However, the inac-
tivation of 14-3-3 σ is probably achieved mainly by hyper-
methylation. Interestingly, 14-3-3 σ turned out to be a very 
significant prognostic indicator in breast cancer, being corre-
lated with poor prognosis, which is the opposite of its previ-
ously known function as a tumor suppressor, suggesting a dif-
ferent role of the 14-3-3 σ in breast cancer.
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